ImmunoPrecise Antibodies (IPA) said Monday that it has made a 'significant contribution' to an anti-aging study led by scientists at the Mayo Clinic.
The biotech firm said the study used its proprietary rabbit B Cell Select platform to isolate and generate antibodies that target phosphorylated ubiquitin, which is an indicator of mitochondrial damage.
"This study advances our understanding of how aging impacts mitochondrial health, a crucial factor in neurodegenerative diseases like Parkinson's and Alzheimer's," the company said.
Price: 0.6497, Change: -0.03, Percent Change: -4.19
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。